Vantage Point Financial
ONCY icon

Vantage Point Financial’s Oncolytics Biotech ONCY Stock Holding History

Vantage Point Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3K Hold
29,744
– – 0.01% 188
2026
Q1 		$25.2K Hold
29,744
– – 0.01% 176
2025
Q4 		$26K Hold
29,744
– – 0.01% 169
2025
Q3 		$41.6K Hold
29,744
– – 0.02% 155
2025
Q2 		$23K Hold
29,744
– – 0.01% 148
2025
Q1 		$16.4K Hold
29,744
– – 0.01% 131
2024
Q4 		$27.2K Buy
+29,744
New +$31K 0.01% 122

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Seeds Investor
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 22.25% 1-Year Est. Return
Connective Capital Management
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Tocqueville Asset Management
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PFG Investments
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Vantage Point Financial's ONCY Position: Q2 2026 in Review

Vantage Point Financial held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 29,744 shares worth $28.3K. The position accounts for 0.01% of the portfolio, ranked #188.

Vantage Point Financial first reported a position in ONCY in Q4 2024 and has held it in 7 quarters since. The position peaked at $41.6K in Q3 2025. 76 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Vantage Point Financial held 29,744 shares of Oncolytics Biotech worth $28.3K as of Q2 2026.
  • Vantage Point Financial left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up 0.01% of Vantage Point Financial's portfolio in Q2 2026, its #188 holding.
  • Vantage Point Financial first reported a position in Oncolytics Biotech in Q4 2024 and has held it in 7 quarters since.
  • Vantage Point Financial's Oncolytics Biotech position peaked at $41.6K in Q3 2025.
  • 76 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Vantage Point Financial's 13F filing for Q2 2026, filed 14 Aug 2026.